Drugs / PL8177
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05466890 | Sep 2022 → Feb 2025 overdue | ulcerative colitis | Palatin Technologies, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-03-28 | Palatin Technologies, Inc | Results Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 palatin.com ↗ |
| 2024-10-24 | Palatin Technologies, Inc | Results Inflammatory Disease Healing Data via Palatin’s Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium palatin.com ↗
Oral PL8177 effectively reduced colonic damage and inflammati |
| 2023-10-16 | Palatin Technologies, Inc | Results Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment palatin.com ↗
Compared to vehicle and the positive control mesalazine, PL8177 showed significant improvements in inflamed colon health, including relative increases in colon cells needed for a healthy colon. |
| 2023-05-30 | Palatin Technologies, Inc | Results Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference palatin.com ↗
The data shows PL8177 treatment of streptozotocin-induced diabetic rats preserved the expression of WT1 protein and the number of podocytes and proximal tubule cells compared to vehicle-treated controls. |
| 2023-05-09 | Palatin Technologies, Inc | Results Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference palatin.com ↗
Clinical data presented in the poster shows that oral PL8177 was released in the GI tract and did not reach systemic circulation. |
| 2023-03-02 | Palatin Technologies, Inc | Results Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease palatin.com ↗
Key findings included maintenance of intact colon structure and barrier, reduced immune cell infiltration, and increased enterocytes with PL8177 treatment. |
| 2023-01-10 | Palatin Technologies, Inc | Results Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions palatin.com ↗
Key findings included PL8177 activation of mouse and human MC1 receptors and that PL8177 displayed pro-resolving activity (enhanced macrophage efferocytosis) and counteracted the inflammatory profile of zymosan-stimulated macrophages, reducing the release of IL-1β, IL-6, TNF-α and CCL-2. |
| 2022-10-24 | Palatin Technologies, Inc | Results Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting palatin.com ↗
The data presented demonstrated that in animal models of ulcerative colitis, oral PL8177 was efficacious in reducing colonic damage and inflammation. |
| 2022-01-21 | Palatin Technologies, Inc | Results Palatin Announces Presentation at the 2022 Crohn’s and Colitis Congress palatin.com ↗
The data presented showed that orally administered PL8177 improved markers of colitis compared to the vehicle group. |
| 2019-10-17 | Palatin Technologies, Inc | Results Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics palatin.com ↗
His presentation outlined how the oral colon delivery formulation of PL8177 effectively addresses the issues of peptide drug delivery and included efficacy data from preclinical ulcerative colitis studies and safety data from Phase 1 clinical studies. |
All press releases naming this drug 14 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL8177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05466890 ↗ |
| Action | Activate | “PL8177 (a melanocortin receptor agonist)” NCT05466890 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3977876 ↗ |
| Route | Oral | “PL8177 will be given orally and daily from baseline until end of study.” NCT05466890 ↗ |